Amgen Inc Data Breach: Sensitive Clinical and Personal Data Exposed

Amgen Inc, a leading biotechnology and pharmaceutical company, reported a data security incident to Indiana authorities on August 17, 2026. The breach, which occurred on July 1, 2026, involved unauthorized access to sensitive data maintained by the company. While the full extent of the compromise is still being assessed, it's clear that confidential information is now at risk.

The exposed data categories include Full Name, Date of Birth, Social Security Number, Clinical Trial Participation Records, Medical History and Treatment Information, Health Insurance ID Number, Mailing Address, and Email Address. This combination of personal identifiers and protected health information creates a high potential for various forms of identity theft and fraud, impacting individuals' financial and medical well-being.

As an entity handling vast amounts of sensitive data, Amgen Inc had a legal obligation to implement robust security measures to protect this information. The occurrence of a breach suggests potential failures in these safeguards, which are mandated under various federal and state regulations designed to ensure data privacy and security.

If you have received a data breach notification letter from Amgen Inc, it confirms that your personal information was part of this compromise. This notification is your starting point for understanding your rights and options. You do not need to have already suffered financial loss to explore potential legal recourse.

Our team is actively investigating this Amgen Inc data breach on behalf of affected individuals. We are committed to helping victims understand their situation and pursue potential compensation without any out-of-pocket costs. Our legal representation is on a contingency fee basis, meaning we only get paid if we secure a recovery for you.